Literature DB >> 22648902

Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses.

Ron J Keizer1, Anthe S Zandvliet, Jos H Beijnen, Jan H M Schellens, Alwin D R Huitema.   

Abstract

In population pharmacokinetic analyses, missing categorical data are often encountered. We evaluated several methods of performing covariate analyses with partially missing categorical covariate data. Missing data methods consisted of discarding data (DROP), additional effect parameter for the group with missing data (EXTRA), and mixture methods in which the mixing probability was fixed to the observed fraction of categories (MIX(obs)), based on the likelihood of the concentration data (MIX(conc)), or combined likelihood of observed covariate data and concentration data (MIX(joint)). Simulations were implemented to study bias and imprecision of the methods in datasets with equal-sized and unbalanced category ratios for a binary covariate as well as datasets with non-random missingness (MNAR). Additionally, the performance and feasibility of implementation was assessed in two real datasets. At either low (10%) or high (50%) levels of missingness, all methods performed similarly well. Performance was similar for situations with unbalanced datasets (3:1 covariate distribution) and balanced datasets. In the MNAR scenario, the MIX methods showed a higher bias in the estimation of CL and covariate effect than EXTRA. All methods could be applied to real datasets, except DROP. All methods perform similarly at the studied levels of missingness, but the DROP and EXTRA methods provided less bias than the mixture methods in the case of MNAR. However, EXTRA was associated with inflated type I error rates of covariate selection, while DROP handled data inefficiently.

Entities:  

Mesh:

Year:  2012        PMID: 22648902      PMCID: PMC3385822          DOI: 10.1208/s12248-012-9373-2

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  14 in total

1.  Assessment of actual significance levels for covariate effects in NONMEM.

Authors:  U Wählby; E N Jonsson; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

Review 2.  Multiple imputation: a primer.

Authors:  J L Schafer
Journal:  Stat Methods Med Res       Date:  1999-03       Impact factor: 3.021

3.  Missing data: our view of the state of the art.

Authors:  Joseph L Schafer; John W Graham
Journal:  Psychol Methods       Date:  2002-06

4.  A weighted estimating equation for linear regression with missing covariate data.

Authors:  Michael Parzen; Stuart R Lipsitz; Joseph G Ibrahim; Steven Lipshultz
Journal:  Stat Med       Date:  2002-08-30       Impact factor: 2.373

5.  Maximum likelihood methods for nonignorable missing responses and covariates in random effects models.

Authors:  Amy L Stubbendick; Joseph G Ibrahim
Journal:  Biometrics       Date:  2003-12       Impact factor: 2.571

6.  Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM.

Authors:  Ron J Keizer; Michel van Benten; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema
Journal:  Comput Methods Programs Biomed       Date:  2010-06-02       Impact factor: 5.428

7.  Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.

Authors:  Tessa M Bosch; Alwin D R Huitema; Valerie D Doodeman; Robert Jansen; Els Witteveen; Wim M Smit; Rob L Jansen; Carla M van Herpen; Marcel Soesan; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Cancer Res       Date:  2006-10-01       Impact factor: 12.531

8.  Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors.

Authors:  Markus Joerger; Alwin D R Huitema; Desiree H J G van den Bongard; Jan H M Schellens; Jos H Beijnen
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

9.  Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.

Authors:  M Joerger; A D R Huitema; H J G D van den Bongard; P Baas; J H Schornagel; J H M Schellens; J H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

10.  Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.

Authors:  Monique M R de Maat; Alwin D R Huitema; Jan W Mulder; Pieter L Meenhorst; Eric C M van Gorp; Jos H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335

View more
  17 in total

1.  Evaluation of Approaches to Deal with Low-Frequency Nuisance Covariates in Population Pharmacokinetic Analyses.

Authors:  Chakradhar V Lagishetty; Stephen B Duffull
Journal:  AAPS J       Date:  2015-06-26       Impact factor: 4.009

2.  Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement.

Authors:  Salmaan Kanji; Meghan Hayes; Adam Ling; Larissa Shamseer; Clarence Chant; David J Edwards; Scott Edwards; Mary H H Ensom; David R Foster; Brian Hardy; Tyree H Kiser; Charles la Porte; Jason A Roberts; Rob Shulman; Scott Walker; Sheryl Zelenitsky; David Moher
Journal:  Clin Pharmacokinet       Date:  2015-07       Impact factor: 6.447

3.  Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Pregnant South African Women with Tuberculosis and HIV.

Authors:  Mahmoud Tareq Abdelwahab; Rory Leisegang; Kelly E Dooley; Jyoti S Mathad; Lubbe Wiesner; Helen McIlleron; Neil Martinson; Ziyaad Waja; Matebogo Letutu; Richard E Chaisson; Paolo Denti
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

4.  Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study.

Authors:  Paolo Denti; Roeland E Wasmann; Annelies van Rie; Jana Winckler; Adrie Bekker; Helena Rabie; Anneke C Hesseling; Louvina E van der Laan; Carmen Gonzalez-Martinez; Heather J Zar; Gerry Davies; Lubbe Wiesner; Elin M Svensson; Helen M McIlleron
Journal:  Clin Infect Dis       Date:  2022-08-24       Impact factor: 20.999

5.  Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection.

Authors:  Kelly E Dooley; Paolo Denti; Neil Martinson; Silvia Cohn; Fildah Mashabela; Jennifer Hoffmann; David W Haas; Jennifer Hull; Regina Msandiwa; Sandra Castel; Lubbe Wiesner; Richard E Chaisson; Helen McIlleron
Journal:  J Infect Dis       Date:  2014-07-31       Impact factor: 5.226

6.  Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.

Authors:  Andrzej Bienczak; Adrian Cook; Lubbe Wiesner; Veronica Mulenga; Cissy Kityo; Addy Kekitiinwa; A Sarah Walker; Andrew Owen; Diana M Gibb; David Burger; Helen McIlleron; Paolo Denti
Journal:  J Antimicrob Chemother       Date:  2016-10-05       Impact factor: 5.790

7.  Age, Weight, and CYP2D6 Genotype Are Major Determinants of Primaquine Pharmacokinetics in African Children.

Authors:  Bronner P Gonçalves; Helmi Pett; Alfred B Tiono; Daryl Murry; Sodiomon B Sirima; Mikko Niemi; Teun Bousema; Chris Drakeley; Rob Ter Heine
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

8.  Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania.

Authors:  Paolo Denti; Kidola Jeremiah; Emmanuel Chigutsa; Daniel Faurholt-Jepsen; George PrayGod; Nyagosya Range; Sandra Castel; Lubbe Wiesner; Christian Munch Hagen; Michael Christiansen; John Changalucha; Helen McIlleron; Henrik Friis; Aase Bengaard Andersen
Journal:  PLoS One       Date:  2015-10-26       Impact factor: 3.240

9.  The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children.

Authors:  Andrzej Bienczak; Adrian Cook; Lubbe Wiesner; Adeniyi Olagunju; Veronica Mulenga; Cissy Kityo; Addy Kekitiinwa; Andrew Owen; A Sarah Walker; Diana M Gibb; Helen McIlleron; David Burger; Paolo Denti
Journal:  Br J Clin Pharmacol       Date:  2016-04-25       Impact factor: 4.335

10.  Population Pharmacokinetics of Methylphenidate in Healthy Adults Emphasizing Novel and Known Effects of Several Carboxylesterase 1 (CES1) Variants.

Authors:  Y K Lyauk; C Stage; T K Bergmann; L Ferrero-Milliani; D Bjerre; R Thomsen; K P Dalhoff; H B Rasmussen; G Jürgens
Journal:  Clin Transl Sci       Date:  2016-10-18       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.